AVXL Anavex Life Sciences Corp.

3.08
-0.14  -4%
Previous Close 3.22
Open 3.22
Price To Book 11
Market Cap 156,257,594
Shares 50,732,985
Volume 466,510
Short Ratio
Av. Daily Volume 558,833

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrolment has reached 40% - noted May 8, 2019.
ANAVEX 2-73
Rett syndrome
Phase 2b enrolment has reached 20% - noted May 8, 2019.
ANAVEX 2-73
Mild to moderate Alzheimer’s disease
Phase 2 enrolment has reached 70% - noted May 8, 2019.
ANAVEX 2-73
Parkinson’s Disease Dementia (PDD)
Phase 2 trial initiation announced June 6, 2019.
ANAVEX 2-73 - AVATAR
Rett syndrome

Latest News

  1. Anavex Life Sciences Announces First Patient Dosed in Extension Study to its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients for Rett Syndrome
  2. Anavex Life Sciences Announces First Patient Dosed in Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Rett Syndrome (AVATAR)
  3. If You Had Bought Anavex Life Sciences (NASDAQ:AVXL) Shares Five Years Ago You'd Have Made 166%
  4. Edited Transcript of AVXL earnings conference call or presentation 8-May-19 8:30pm GMT
  5. Rett Syndrome Association of Australia and Anavex Life Sciences Announce Initiation of the Phase 2 AVATAR Clinical Study in Patients with Rett Syndrome
  6. Anavex Life Sciences: Fiscal 2Q Earnings Snapshot
  7. Anavex Life Sciences Reports Fiscal 2019 Second Quarter Financial Results and Provides Clinical Study Updates
  8. Anavex Life Sciences to Announce Fiscal 2019 Second Quarter Financial Results on Wednesday May 8th, 2019
  9. Anavex Life Sciences to Present at the H.C. Wainwright Annual Global Life Sciences Conference
  10. Anavex Life Sciences Presents Data On ANAVEX®2-73 in Alzheimer’s Disease at the American Society for Experimental Neurotherapeutics - ASENT 2019 Annual Meeting
  11. Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development
  12. Anavex- Searching for Treatments to Parkinson's and Alzheimer's
  13. Anavex Life Sciences Announces First Patient Dosed in Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Rett Syndrome in the U.S.
  14. Anavex Life Sciences to Present at the 31st Annual ROTH Conference 2019
  15. Anavex Life Sciences Reaches 50% Enrollment Threshold in ANAVEX®2-73 Parkinson’s Disease Dementia (PDD) Phase 2 Study Ahead of Schedule
  16. Anavex Life Sciences to Present at the Cowen 39th Annual Health Care Conference 2019
  17. Anavex Life Sciences Reports Publication of New Data that Show ANAVEX®2-73 Induces Cellular Recycling Process Linked to the Prevention and Treatment of Age-Associated Diseases
  18. Edited Transcript of AVXL earnings conference call or presentation 7-Feb-19 9:30pm GMT
  19. Market Trends Toward New Normal in GameStop, Novo Nordisk A/S, Ferroglobe, PC Connection, Nanometrics, and Anavex Life Sciences — Emerging Consolidated Expectations, Analyst Ratings